scholarly journals Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review

2015 ◽  
Vol 19 (1) ◽  
pp. 68-71 ◽  
Author(s):  
A Leone ◽  
B Gershman ◽  
K Rotker ◽  
C Butler ◽  
J Fantasia ◽  
...  
Keyword(s):  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation ◽  
Institutional Review

MP14-17 IMMEDIATE REPEAT BIOPSY IS NOT NECESSARY IN PATIENTS WITH ATYPICAL SMALL ACINAR PROLIFERATION (ASAP): A MULTI-INSTITUTIONAL REVIEW

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Andrew Leone ◽  
Boris Gershman ◽  
Katherine Rotker ◽  
Christi Butler ◽  
Jennifer Fantasia ◽  
...  
Keyword(s):  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation ◽  
Institutional Review

scholarly journals Rate of Gleason 7 or higher prostate cancer on repeat biopsy after a diagnosis of atypical small acinar proliferation

2015 ◽  
Vol 18 (3) ◽  
pp. 255-259 ◽  
Author(s):  
C Warlick ◽  
K Feia ◽  
J Tomasini ◽  
C Iwamoto ◽  
B Lindgren ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation

scholarly journals Implementation of repeat biopsy and detection of cancer after a diagnosis of atypical small acinar proliferation of the prostate

2020 ◽  
Vol 13 (6) ◽  
pp. 1-1
Author(s):  
Takahiro Imanaka ◽  
Takahiro Yoshida ◽  
Ayumu Taniguchi ◽  
Kazuaki  Yamanaka ◽  
Hidefumi Kishikawa ◽  
...  
Keyword(s):  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation

MP60-17 DOES ATYPICAL SMALL ACINAR PROLIFERATION ON 1ST REPEAT BIOPSY INCREASE PROSTATE CANCER DETECTION?

2015 ◽  
Vol 193 (4S) ◽  
Author(s):  
Ahmed Elshafei ◽  
Ayman S. Moussa ◽  
Heather Neifert ◽  
Ganesh Kartha ◽  
J. Stephen Jones
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Repeat Biopsy ◽  
Prostate Cancer Detection ◽  
Atypical Small Acinar Proliferation

Targeted second repeat biopsy for atypical small acinar proliferation after first set of systematic prostate rebiopsy

2016 ◽  
Vol 15 (5) ◽  
pp. e1176
Author(s):  
A. Karman ◽  
S. Shymanets ◽  
A. Rolevich ◽  
A. Minich ◽  
S. Krasny
Keyword(s):  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation

Rate of clinically significant prostate cancer on repeat saturation biopsy after a diagnosis of atypical small acinar proliferation

2021 ◽  
pp. 039156032199359
Author(s):  
Angelo Totaro ◽  
Luca Di Gianfrancesco ◽  
Francesco Pinto ◽  
Marco Racioppi ◽  
Giuseppe Palermo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Prostate Biopsy ◽  
Initial Diagnosis ◽  
Repeat Biopsy ◽  
Atypical Small Acinar Proliferation ◽  
Saturation Biopsy ◽  
Prostate Biopsies ◽  
History Of ◽  
Clinically Significant

Background: Atypical small acinar proliferation (ASAP) occurs in approximately 5% of prostate biopsies. Approximately 30%–40% of these patients may develop prostate cancer (PCa) within a 5-year period, often not clinically significant. Current guidelines recommend a repeat biopsy within 3–6 months after the initial diagnosis, but it seem not to be the best strategy. Methods: Objectives—evaluating the natural history of ASAP, stratifying the risk of csPCa after ASAP, identifying predictive factors of PCa after atypical diagnosis. Materials and methods—retrospective single-institutional study on patients undergoing prostate biopsy for suspicious PCa (2005–2016). We evaluated the incidence of overall PCa, intermediate-high risk of PCa and csPCa in case of ASAP, according to D’Amico classification and Epstein modified criteria. Results: Out of 4.567 patients undergoing prostate biopsy, ASAP was detected in 2.6% of cases. All patients with ASAP underwent repeat saturation biopsy within 6 months and PCa was diagnosed in 34.5%. According to D’Amico classification, 26%, 5.9%, and 2.5% had low, intermediate, and high-risk disease, respectively. According modified Epstein criteria, the incidence of csPCa was 12.6%. LRT showed that the overall probability to develop PCa doubled when PSA density (PSAD) moved from values lower than 0.13 ng/ml/cc to class 0.13–0.30 ng/ml/cc, and it tripled when PSAD was higher than 0.30 ng/ml/cc. Conclusions: The rate of csPCa in patients with an initial diagnosis of ASAP who had repeat biopsy was 12.6%. The overall PCa rate was 34.5%. Among patient undergoing RP, an upgrading from ncsPCa to csPCa was reported in 35% of cases. PSAD is the only predictive factor directly associated to the risk of developing PCa on repeat biopsy. These findings suggest that immediate repeat biopsy remains the correct strategy in absence of novel predictor factors and non-invasive diagnostic evaluations.

Sign in / Sign up

Export Citation Format

Share Document